Peri-ImplantitisPERI-EDUNCT07012915
Immunological-Clinical Evaluation of the Etiopathogenesis of Peri-Implantitis
A study testing Blood testing in people with Peri-Implantitis, run by Wroclaw Medical University at 1 site in Poland.
Trial summary
A total of 100 adult volunteers of both sexes will be enrolled in the project. The study will be conducted within an international consortium formed for the project, comprising the following institutions: Wroclaw Medical University (Poland), Sapienza University of Rome (Italy), University of Barcelona (Spain)… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Peri-Implantitis
- What is being tested?
- Blood testing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 sitePoland
- Study dates
- 1 Jul 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- PD (Pocket Depth) at the implant site exceeds 6mm,
- Positive BoP (Bleeding on Probing) index
- Bone loss exceeding 66% on at least one implant surface
Who cannot join
- General and local contraindications for surgical procedures
- Pregnancy
- Use of bisphosphonates or other antiresorptive medications in medical history
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Oral Surgery Department Wroclaw Medical University
Wroclaw, Lower Silesian Voivodeship, 50425
Paweł Kubasiewicz-Ross, PhD, DDS, 504075920 ext. +48, pawel.kubasiewicz-ross@umw.edu.pl
Jacek Matys, PhD, DDS, 791511789 ext. +48, jacek.matys@umw.edu.pl
About this study
A total of 100 adult volunteers of both sexes will be enrolled in the project. The study will be conducted within an international consortium formed for the project, comprising the following institutions: Wroclaw Medical University (Poland), Sapienza University of Rome (Italy), University of Barcelona (Spain), University of Bern (Switzerland), and Egas Moniz University (Portugal). Each international partner institution will recruit 20 volunteers as participants in the experiment. Each of the participating institutions will submit an application to their respective local bioethics committee for approval to conduct the medical experiment. Each partner institution will conduct procedures at their respective clinical locations.
Eligibility Criteria participants must have undergone previous implant treatment that has resulted in active, advanced peri-implantitis. Exclusion Criteria: General and local contraindications for surgical procedures Pregnancy; Use of bisphosphonates or other antiresorptive medications in medical history Laboratory Analysis Procedures.
Read more
During the initial visit, patients will undergo a medical interview and a dental examination with regard to: Oral Hygiene Indices; Periodontal disease indices. For the implant site, the following parameters will be evaluated: Pocket Depth Bleeding on Probing Width and height of the attached gingiva Possible implant mobility, assessed using the Mobility Index Following the clinical examination, each participant will be referred for a Cone Beam Computed Tomography (CBCT) scan with measurements including: Bone loss percentage for each of the four implant surfaces, Bone density. Next, a 20ml venous blood sample will be collected from the antecubital vein of each participant and sent to a laboratory for further analysis, including: Hematological Inflammation Indices: Systemic Immune-Inflammation Index, Aggregate Index of Systemic Inflammation, Complete blood count, Lipid profile, APOA., APOBg, Inflammatory markers, albumin, total protein, total ferritin, fibrinogen, Cytokine profile, HOMA2 Parameters, Thyroid profile, Vitamin D level Next, each participant will undergo implant explantation surgery, during which tissue samples will be collected for further analysis. Implant surface will be analyzed using: light microscopy, scanning electron microscopy, corrosion testing.
Follow-Up will be scheduled four weeks later with following evaluation: Clinical assessment of the implantation site. A CBCT scan to assess bone structure in the post-implantation region, with measurements including percentage of bone loss. Moreover, 20ml of venous blood will be collected from the antecubital vein of each participant. The blood sample will be preserved and sent to an analytical laboratory for further testing, including for same as previously mentioned tests.
Read the detailed description
The following research experiment project is part of the scientific section of a project funded under the Erasmus+ program (KA220-HED - Cooperation partnerships in higher education) entitled "Integrating Peri-Implantitis Research into Higher Education Curriculum - Developing and Integrating Evidence-Based Teaching Materials and Clinical Tools." According to the current state of knowledge, there are two main theories explaining the development of peri-implantitis. The first theory suggests that the primary etiological factor is the invasion of periopathogens along the gingival crevice surrounding the implant, resembling the pathogenic development seen in natural periodontal diseases such as gingivitis and periodontitis. In this scenario, bacterial invasion is facilitated by the distinct structure of the peri-implant soft tissues, which differ from natural gingival tissue in several ways: a more uniaxial, parallel orientation of collagen fibers relative to the implant's long axis, lower cellular density, and reduced mitotic potential of the surrounding soft tissue.
The second theory proposes that marginal bone loss around the implant is the result of an immuno-osteolytic reaction, with pathogenic bacteria appearing as a secondary phenomenon. According to this theory, the initiation of the pathological process is attributed to an immune response triggered by the presence of titanium ions and other metallic elements, such as vanadium, which is commonly found in titanium alloys. In vitro models have demonstrated that an increase in Ti concentration leads to macrophage activation and increased secretion of pro-inflammatory cytokines, particularly interleukin IL-1B and arachidonic acid derivatives. This macrophage activation is significantly higher in cases where prior bacterial lipopolysaccharide (LPS) exposure has occurred, suggesting an additive effect of bacterial factors in the overall disease process. Furthermore, vanadium appears to disrupt the balance of T/B lymphocytes, suppress the secretion of anti-inflammatory cytokines, and activate the innate immune response via Toll-like receptors and NF-κB signaling pathways.
Despite conceptual differences between these two theories, both agree on the fundamental premise that biological processes occurring on the implant surface and in its immediate vicinity play a critical role in the development of peri-implantitis. These processes are modulated by the physicochemical properties of the implant surface.
The immuno-osteolytic concept of peri-implantitis, also known as the foreign body reaction theory, is largely based on physicochemical changes that occur on the implant surface over time due to its exposure to the oral tissue environment. These changes are associated with gradual degradation, corrosion, and aging of titanium alloys.
In biomedical applications, biphasic titanium alloys are most commonly used, particularly the Ti-6Al-4V alloy, which contains 6% aluminum and 4% vanadium. Aluminum stabilizes the α-phase, improving mechanical strength and reducing weight, while vanadium stabilizes the β-phase, enhancing alloy plasticity.
All known metals and alloys undergo corrosion under specific conditions. Most of them are thermodynamically unstable, tending to transition from their metallic state to ionic form. The degree of thermodynamic stability of a metal is characterized by its standard electrode potential, which describes the free energy change when an ion transitions from the metal to a solution. The more negative the standard electrode potential, the lower the metal's resistance to corrosion. The standard ionization potential of titanium is theoretically established at 1.63V, indicating high electrochemical potential and corrosion susceptibility of pure titanium. However, in practice, titanium exhibits lower corrosion potential due to its tendency to undergo passivation, forming a stable oxide layer that acts as a barrier preventing direct contact between the metal and the external environment.
The stability of the titanium dioxide (TiO₂) passive layer in the oral cavity is compromised by salivary enzymes and bacterial metabolism, particularly acidic byproducts such as lactic, acetic, and propionic acids. These substances create localized pH shifts towards acidity, which are unfavorable for titanium alloys and accelerate corrosion. Another factor increasing titanium corrosion in dental applications is the presence of fluoride compounds, which are commonly used in toothpaste, mouthwashes, gels, and fluoride foams. In aqueous solutions, fluoride exists primarily as the fluoride ion (F-), which has the ability to dissolve the passive oxide layer on titanium, significantly increasing corrosion rates.
A separate concern is the fatigue-related degradation of titanium implants. These fatigue processes are associated with repeated mechanical stress, particularly non-linear loading patterns. The first observable sign of fatigue is the formation of microcracks, detectable via scanning electron microscopy (SEM). In advanced stages, these microcracks lead to wear-corrosion phenomena, further accelerating surface degradation of titanium alloys.
Objectives of the Medical Experiment:
Clinical assessment of oral health, with a particular focus on periodontal indicators and oral hygiene status in participants affected by peri-implantitis.
Radiological evaluation of bone structure affected by peri-implantitis. Hematological assessment of peri-implantitis markers and the immunological profile of participants diagnosed with peri-implantitis.
Measurement of Ti++ ion concentrations and other metallic elements present in titanium alloys in tissues surrounding implants affected by peri-implantitis.
Corrosion analysis and SEM-based fatigue analysis of implant surfaces associated with peri-implantitis.
Study design A total of 100 adult volunteers of both sexes will be enrolled in the project. The study will be conducted within an international consortium formed for the project, comprising the following institutions: Wroclaw Medical University (Poland), Sapienza University of Rome (Italy), University of Barcelona (Spain), University of Bern (Switzerland), and Egas Moniz University (Portugal).
Each international partner institution will recruit 20 volunteers as participants in the experiment. Each of the participating institutions (Sapienza University of Rome, University of Barcelona, University of Bern, and Egas Moniz University) will submit an application to their respective local bioethics committee for approval to conduct the medical experiment.
Eligibility Criteria To be eligible for the study, participants must have undergone previous implant treatment that has resulted in active, advanced peri-implantitis.
During the initial visit, patients will undergo a medical interview to document their systemic diseases and dental treatment history, with particular emphasis on:
The type and brand of implant The prosthetic loading type of the implant The location and time of implantation The onset and treatment history of peri-implantitis
Each participant will then undergo a dental examination, utilizing a UNC15 periodontal probe (DepplerSA, Roller, Switzerland). This assessment will include:
Oral hygiene indicators: Oral Hygiene Index (OHI), Aproximal Plaque Index (API) Periodontal disease indices: Community Index of Periodontal Treatment Needs (CPITN) Occlusal abnormalities and increased facial muscle tension, particularly in the mentalis muscle and oral floor muscles Implant-Specific Assessments
For the implant site, the following parameters will be evaluated:
Pocket Depth (PD) - measured on four surfaces around the implant Bleeding on Probing (BoP) Index Width and height of the attached gingiva (HKT, WKT) Possible implant mobility, assessed using the Mobility Index (MOB) Following the clinical examination, each participant will be referred for a Cone Beam Computed Tomography (CBCT) scan.
CBCT Examination
The CBCT scan will be routinely evaluated, focusing on the implant region, with measurements including:
Bone loss percentage, calculated as the ratio of bone defect depth from the implant platform to the base of the defect, relative to the total implant length, assessed separately for each of the four implant surfaces (mesial, distal, buccal, and lingual/palatal).
Bone density, measured in Hounsfield units (HU)
A peri-implantitis process will be classified as active if:
PD at the implant site exceeds 6mm, with a positive BoP index Advanced peri-implantitis is diagnosed if bone loss exceeds 66% on at least one implant surface Treatment Eligibility Criteria According to established literature, in cases of active, advanced peri-implantitis, where bone loss exceeds 50% of the implant length, implant removal is considered the appropriate therapeutic approach. Only patients meeting this criterion will be enrolled in the project.
Exclusion Criteria:
General and local contraindications for surgical procedures Pregnancy Use of bisphosphonates or other antiresorptive medications in medical history Patients who do not meet the implant removal criteria and are not eligible for the study will be directed toward non-surgical or conservative-surgical treatment options.
Laboratory Analysis Procedures
During a subsequent procedural visit, a 20ml venous blood sample will be collected from the antecubital vein of each participant. The blood samples will be preserved in EDTA tubes and sent to a laboratory for further analysis, including:
Hematological Inflammation Indices: Systemic Immune-Inflammation Index (SII), Aggregate Index of Systemic Inflammation (AISI), Complete blood count with quantitative and percentage analysis, Indicator of Peri-Implantitis and Periodontal Disease Development: morphology by quantitative and percentage separation, Lipid profile: (CHOL , HDL, LDL, TG, APOA1, APOB);
- Inflammatory markers: CRP, ESR, ALB, TP, TF, FIB;
- Cytokine profile: TNF, IL- 1β, IL-6, IL-8, IL-10;
- HOMA2 Parameters: Glucose, Insulin, C-Peptide, HBA1;
- Thyroid profile:- TSH, FT3, FT4, T3, T4, rT3;
- Vitamin D level - 25(OH)D, 1.25(OH)2 D3 Laboratory and Surgical Procedures Each partner institution will conduct laboratory tests and clinical procedures at their respective clinical locations, in collaboration with a certified analytical laboratory.
Next, each participant will undergo implant explantation surgery, during which tissue samples will be collected for further analysis, followed by immediate bone defect regeneration at the implantation site. The procedure will be preceded by removal of the prosthetic restoration.
Following oral disinfection with a 0.2% alcohol-based chlorhexidine solution, local infiltration anesthesia will be administered using 2% articaine with epinephrine 1:200,000. A flap incision will be performed to access the peri-implant region.
A trephine drill with the smallest possible diameter will then be selected to encompass the implant collar. Using the following drilling parameters-800 rpm, 20 Ncm torque, and 0.9% NaCl irrigation-the drill will be lowered to the apical depth of the implant. The implant will be extracted along with any bone tissue tightly adhered to its surface.
The implant and bone tissue will be preserved in a 5% formalin solution. The surgical site will be sutured using non-resorbable 5-0 monofilament sutures.
Both specimens will be sent to research centers in Poland. The implant and tissue samples will be transferred to the Department of Inorganic Chemistry, Analytical Chemistry, and Electrochemistry at the Silesian University of Technology in Gliwice, Poland.
Laboratory Analysis
In the laboratory, biological material will be separated from the samples. The following analyses will be performed:
Titanium concentration measurement and detection of other metals present in the titanium alloy.
Implant surface will be analysed using: Light microscopy, Scanning electron microscopy (SEM), corrosion testing. The microscopic examination will assess the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Post-Explantation Follow-Up
One week after the explantation procedure, a follow-up visit will take place. During this visit:
Surgical sutures will be removed. The healing process of the surgical wound will be assessed. If no complications are detected, the next follow-up visit will be scheduled four weeks later. During the four-week follow-up visit, the following evaluations will be performed:
Clinical assessment of the implantation site, including HKT and WKT parameters A second CBCT scan: to assess bone structure in the post-implantation region, with measurements including: Percentage of bone loss, calculated as the ratio of the smallest vertical dimension of the alveolar ridge in the post-implantation area to the height of the alveolar ridge in the immediate vicinity
Blood Sample Collection:
20ml of venous blood will be collected from the antecubital vein of each participant.
The blood sample will be preserved in EDTA tubes and sent to an analytical laboratory for further testing, including same parameters as mentioned previously.
- Conditions
- Peri-Implantitis
- Being tested
- Blood testing
- Keywords
- Perii-implantitis, Titanium alloys corosion, Titanium implants
- Medical subject headings
- Peri-Implantitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood testingDiagnostic test
Also called Radiation, Surgery
Blood sample will be collected twice for each participants procedding and following dental implant removal. Cone Beam Computed Tomography will be applied to evaluate the shape, severity of bone defect in direct viscinity of the implant.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Experimental | Every participant will achieve same intervention when it comes to surgical treatment, clinical examination, radiology evaluation and defined parameters of blood serum. Receives: Diagnostic Test: Blood testing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood testing, total blood count, and indices derived from it.
Hematological Inflammation Indices: Systemic Immune-Inflammation Index (SII) calculated as follows: SII=NEUxPLT/LYMPH
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, total blood count, and indices derived from it.
Hematological Inflammation Indices: Aggregate Index of Systemic Inflammation (AISI) calculated as follows: AISI= NEU×PLTxMON/LYMP
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, lipid profile.
CHOL mg/dl , HDL mg/dl, LDL mg/dl, TG mg/dl, APOA1 mg/dl, APOB mg/dl
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Inflammatory markers.
Inflammatory markers: CRP mg/l, albumin (ALB) mg/dl, TP mg/dl,TF mg/dl, FIB mg/dl
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Inflammatory marker.
ESR mm/h
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Cytokine profile.
TNF- α pg/ml , IL- 1β pg/ml, IL-6 pg/ml, IL-8 pg/ml, IL-10 pg/ml
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, HOMA2 Parameters
HOMA2 Parameters - Glucose mg/dl, C-Peptide mg/dl,
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, HOMA2 Parameters
Insulin mU/ml
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, HOMA2 Parameters
HBA1C %
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Thyroid profile
TSH μIU/ml
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Thyroid profile
FT3 ng/l, FT4 ng/l
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Thyroid profile
T3 ng/dl, T4 ng/dl
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Thyroid profile
rT3 ng/ml
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Blood testing, Vitamin D3 level
25(OH)D, 1.25(OH)2 D3 ng/ml
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Clinical examination - general, oral cavity
Oral Hygiene Index (OHI) %, Aproximal Plaque Index (API) %
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Clinical examination - general, oral cavity, utilizing a UNC15 periodontal probe
Community Index of Periodontal Treatment Needs (CPITN)
Measured: On the day of implant removal (before implant removal).
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Pocket Depth (PD) - measured on four surfaces around the implant in mm.
Measured: On the day of implant removal (before implant removal).
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Bleeding on Probing (BoP) Index - Yes or No. (0 or 1).
Measured: On the day of implant removal (before implant removal).
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Width and height of the attached gingiva (HKT, WKT) in mm.
Measured: On the day of implant removal (before implant removal).
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Possible implant mobility, assessed using the Mobility Index (MOB) acc to Misch, Grade: 0,1,2 or 3
Measured: On the day of implant removal (before implant removal).
Radiology-based evaluation
Cone-Beam Computed Tomography: Bone loss percentage on the implant site (%), calculated as the ratio of bone defect depth from the implant platform to the base of the defect, relative to the total implant length, assessed separately for each of the four implant surfaces (mesial, distal, buccal, and lingual/palatal)
Measured: On the day of implant removal (before implant removal).
Radiology-based evaluation
Cone-Beam Computed Tomography: Bone density on the implant site (before and after implant removal), measured in Hounsfield units (HU)
Measured: On the day of implant removal (before implant removal) and 4 weeks after.
Implant surface evaluation, light microscopy
Assessment of the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Measured: Within 48 hours after implant removal
Implant surface evaluation, Scanning electron microscopy
Assessment of the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Measured: Within 48 hours after implant removal
Implant surface evaluation - detection of other metals presented in the titanium alloy.
Energy-dispersive X-ray spectroscopy (EDS)
Measured: Within 48 hours after implant removal
Titanium ions concentration in tissues attached to implant' surface
Inductively coupled plasma mass spectrometry (ICP-MS)
Measured: Within 48 hours after implant removal
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study start1 Jul 2025
- Primary completion1 Apr 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Peri-ImplantitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Healthy adult participants, suffering from Peri-Implantitis. Every participant from a total number of 100 will have blood sample collected twice before and 4 weeks following implant removal for detailed evaluation. Furthermore, the Cone Beam Computed Tomography will be applied to evaluate the severity and shape of bone defect. Removed implants will be send for detailed chemical evaluation.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wroclaw Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- University of Bern, University of Barcelona, University of Roma La Sapienza, Egas Moniz - Cooperativa de Ensino Superior, CRL
- Responsible party
- Sponsor
- Investigators
- Marzena Dominiak, Prof, Study chair, Wroclaw Medical Univeristy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07012915
- Sponsor's protocol ID
- KA220-HED
- Acronym
- PERI-EDU
- Status last verified
- May 2025
- First submitted
- 14 May 2025
- Last updated
- 10 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected anonymized IPD will be available on Zenodo Repository.
Publications
Elani HW, Starr JR, Da Silva JD, Gallucci GO. Trends in Dental Implant Use in the U.S., 1999-2016, and Projections to 2026. J Dent Res. 2018 Dec;97(13):1424-1430. doi: 10.1177/0022034518792567. Epub 2018 Aug 3.
PubMed 30075090Fu JH, Wang HL. Breaking the wave of peri-implantitis. Periodontol 2000. 2020 Oct;84(1):145-160. doi: 10.1111/prd.12335.
PubMed 32844418Schwarz F, Claus C, Becker K. Correlation between horizontal mucosal thickness and probing depths at healthy and diseased implant sites. Clin Oral Implants Res. 2017 Sep;28(9):1158-1163. doi: 10.1111/clr.12932. Epub 2016 Jul 26.
PubMed 27458093Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. J Periodontol. 2018 Jun;89 Suppl 1:S267-S290. doi: 10.1002/JPER.16-0350.
PubMed 29926957Albrektsson T, Canullo L, Cochran D, De Bruyn H. "Peri-Implantitis": A Complication of a Foreign Body or a Man-Made "Disease". Facts and Fiction. Clin Implant Dent Relat Res. 2016 Aug;18(4):840-9. doi: 10.1111/cid.12427. Epub 2016 May 30.
PubMed 27238274Pettersson M, Kelk P, Belibasakis GN, Bylund D, Molin Thoren M, Johansson A. Titanium ions form particles that activate and execute interleukin-1beta release from lipopolysaccharide-primed macrophages. J Periodontal Res. 2017 Feb;52(1):21-32. doi: 10.1111/jre.12364. Epub 2016 Mar 14.
PubMed 26987886Tsave O, Petanidis S, Kioseoglou E, Yavropoulou MP, Yovos JG, Anestakis D, Tsepa A, Salifoglou A. Role of Vanadium in Cellular and Molecular Immunology: Association with Immune-Related Inflammation and Pharmacotoxicology Mechanisms. Oxid Med Cell Longev. 2016;2016:4013639. doi: 10.1155/2016/4013639. Epub 2016 Apr 11.
PubMed 27190573Scibior A, Pietrzyk L, Plewa Z, Skiba A. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. J Trace Elem Med Biol. 2020 Sep;61:126508. doi: 10.1016/j.jtemb.2020.126508. Epub 2020 Apr 12.
PubMed 32305626Grande F, Tucci P. Titanium Dioxide Nanoparticles: a Risk for Human Health? Mini Rev Med Chem. 2016;16(9):762-9. doi: 10.2174/1389557516666160321114341.
PubMed 26996620Zhang HM, Cao J, Tang BP, Wang YQ. Effect of TiO(2) nanoparticles on the structure and activity of catalase. Chem Biol Interact. 2014 Aug 5;219:168-74. doi: 10.1016/j.cbi.2014.06.005. Epub 2014 Jun 12.
PubMed 24931876Chen WQ, Zhang SM, Qiu J. Surface analysis and corrosion behavior of pure titanium under fluoride exposure. J Prosthet Dent. 2020 Aug;124(2):239.e1-239.e8. doi: 10.1016/j.prosdent.2020.02.022. Epub 2020 May 10.
PubMed 32402439Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Effect of modification of oxide layer on NiTi stent corrosion resistance. J Biomed Mater Res. 1998 Winter;43(4):433-40. doi: 10.1002/(sici)1097-4636(199824)43:43.0.co;2-#.
PubMed 9855202Chouirfa H, Bouloussa H, Migonney V, Falentin-Daudre C. Review of titanium surface modification techniques and coatings for antibacterial applications. Acta Biomater. 2019 Jan 1;83:37-54. doi: 10.1016/j.actbio.2018.10.036. Epub 2018 Oct 26.
PubMed 30541702
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunological-Clinical Evaluation of the Etiopathogenesis of Peri-Implantitis
- ClinicalTrials.gov ID
- NCT07012915
- Acronym / sponsor ID
- PERI-EDU / KA220-HED
- Conditions
- Peri-Implantitis
- Keywords
- Perii-implantitis, Titanium alloys corosion, Titanium implants
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Wroclaw Medical UniversityUniversity, hospital or other
- Collaborators
- University of Bern, University of Barcelona, University of Roma La Sapienza, Egas Moniz - Cooperativa de Ensino Superior, CRL
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 10 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A total of 100 adult volunteers of both sexes will be enrolled in the project. The study will be conducted within an international consortium formed for the project, comprising the following institutions: Wroclaw Medical University (Poland), Sapienza University of Rome (Italy), University of Barcelona (Spain), University of Bern (Switzerland), and Egas Moniz University (Portugal). Each international partner institution will recruit 20 volunteers as participants in the experiment. Each of the participating institutions will submit an application to their respective local bioethics committee for approval to conduct the medical experiment. Each partner institution will conduct procedures at their respective clinical locations.
Eligibility Criteria participants must have undergone previous implant treatment that has resulted in active, advanced peri-implantitis. Exclusion Criteria: General and local contraindications for surgical procedures Pregnancy; Use of bisphosphonates or other antiresorptive medications in medical history Laboratory Analysis Procedures.
During the initial visit, patients will undergo a medical interview and a dental examination with regard to: Oral Hygiene Indices; Periodontal disease indices. For the implant site, the following parameters will be evaluated: Pocket Depth Bleeding on Probing Width and height of the attached gingiva Possible implant mobility, assessed using the Mobility Index Following the clinical examination, each participant will be referred for a Cone Beam Computed Tomography (CBCT) scan with measurements including: Bone loss percentage for each of the four implant surfaces, Bone density. Next, a 20ml venous blood sample will be collected from the antecubital vein of each participant and sent to a laboratory for further analysis, including: Hematological Inflammation Indices: Systemic Immune-Inflammation Index, Aggregate Index of Systemic Inflammation, Complete blood count, Lipid profile, APOA., APOBg, Inflammatory markers, albumin, total protein, total ferritin, fibrinogen, Cytokine profile, HOMA2 Parameters, Thyroid profile, Vitamin D level Next, each participant will undergo implant explantation surgery, during which tissue samples will be collected for further analysis. Implant surface will be analyzed using: light microscopy, scanning electron microscopy, corrosion testing.
Follow-Up will be scheduled four weeks later with following evaluation: Clinical assessment of the implantation site. A CBCT scan to assess bone structure in the post-implantation region, with measurements including percentage of bone loss. Moreover, 20ml of venous blood will be collected from the antecubital vein of each participant. The blood sample will be preserved and sent to an analytical laboratory for further testing, including for same as previously mentioned tests.
Detailed description
The following research experiment project is part of the scientific section of a project funded under the Erasmus+ program (KA220-HED - Cooperation partnerships in higher education) entitled "Integrating Peri-Implantitis Research into Higher Education Curriculum - Developing and Integrating Evidence-Based Teaching Materials and Clinical Tools." According to the current state of knowledge, there are two main theories explaining the development of peri-implantitis. The first theory suggests that the primary etiological factor is the invasion of periopathogens along the gingival crevice surrounding the implant, resembling the pathogenic development seen in natural periodontal diseases such as gingivitis and periodontitis. In this scenario, bacterial invasion is facilitated by the distinct structure of the peri-implant soft tissues, which differ from natural gingival tissue in several ways: a more uniaxial, parallel orientation of collagen fibers relative to the implant's long axis, lower cellular density, and reduced mitotic potential of the surrounding soft tissue.
The second theory proposes that marginal bone loss around the implant is the result of an immuno-osteolytic reaction, with pathogenic bacteria appearing as a secondary phenomenon. According to this theory, the initiation of the pathological process is attributed to an immune response triggered by the presence of titanium ions and other metallic elements, such as vanadium, which is commonly found in titanium alloys. In vitro models have demonstrated that an increase in Ti concentration leads to macrophage activation and increased secretion of pro-inflammatory cytokines, particularly interleukin IL-1B and arachidonic acid derivatives. This macrophage activation is significantly higher in cases where prior bacterial lipopolysaccharide (LPS) exposure has occurred, suggesting an additive effect of bacterial factors in the overall disease process. Furthermore, vanadium appears to disrupt the balance of T/B lymphocytes, suppress the secretion of anti-inflammatory cytokines, and activate the innate immune response via Toll-like receptors and NF-κB signaling pathways.
Despite conceptual differences between these two theories, both agree on the fundamental premise that biological processes occurring on the implant surface and in its immediate vicinity play a critical role in the development of peri-implantitis. These processes are modulated by the physicochemical properties of the implant surface.
The immuno-osteolytic concept of peri-implantitis, also known as the foreign body reaction theory, is largely based on physicochemical changes that occur on the implant surface over time due to its exposure to the oral tissue environment. These changes are associated with gradual degradation, corrosion, and aging of titanium alloys.
In biomedical applications, biphasic titanium alloys are most commonly used, particularly the Ti-6Al-4V alloy, which contains 6% aluminum and 4% vanadium. Aluminum stabilizes the α-phase, improving mechanical strength and reducing weight, while vanadium stabilizes the β-phase, enhancing alloy plasticity.
All known metals and alloys undergo corrosion under specific conditions. Most of them are thermodynamically unstable, tending to transition from their metallic state to ionic form. The degree of thermodynamic stability of a metal is characterized by its standard electrode potential, which describes the free energy change when an ion transitions from the metal to a solution. The more negative the standard electrode potential, the lower the metal's resistance to corrosion. The standard ionization potential of titanium is theoretically established at 1.63V, indicating high electrochemical potential and corrosion susceptibility of pure titanium. However, in practice, titanium exhibits lower corrosion potential due to its tendency to undergo passivation, forming a stable oxide layer that acts as a barrier preventing direct contact between the metal and the external environment.
The stability of the titanium dioxide (TiO₂) passive layer in the oral cavity is compromised by salivary enzymes and bacterial metabolism, particularly acidic byproducts such as lactic, acetic, and propionic acids. These substances create localized pH shifts towards acidity, which are unfavorable for titanium alloys and accelerate corrosion. Another factor increasing titanium corrosion in dental applications is the presence of fluoride compounds, which are commonly used in toothpaste, mouthwashes, gels, and fluoride foams. In aqueous solutions, fluoride exists primarily as the fluoride ion (F-), which has the ability to dissolve the passive oxide layer on titanium, significantly increasing corrosion rates.
A separate concern is the fatigue-related degradation of titanium implants. These fatigue processes are associated with repeated mechanical stress, particularly non-linear loading patterns. The first observable sign of fatigue is the formation of microcracks, detectable via scanning electron microscopy (SEM). In advanced stages, these microcracks lead to wear-corrosion phenomena, further accelerating surface degradation of titanium alloys.
Objectives of the Medical Experiment:
Clinical assessment of oral health, with a particular focus on periodontal indicators and oral hygiene status in participants affected by peri-implantitis.
Radiological evaluation of bone structure affected by peri-implantitis. Hematological assessment of peri-implantitis markers and the immunological profile of participants diagnosed with peri-implantitis.
Measurement of Ti++ ion concentrations and other metallic elements present in titanium alloys in tissues surrounding implants affected by peri-implantitis.
Corrosion analysis and SEM-based fatigue analysis of implant surfaces associated with peri-implantitis.
Study design A total of 100 adult volunteers of both sexes will be enrolled in the project. The study will be conducted within an international consortium formed for the project, comprising the following institutions: Wroclaw Medical University (Poland), Sapienza University of Rome (Italy), University of Barcelona (Spain), University of Bern (Switzerland), and Egas Moniz University (Portugal).
Each international partner institution will recruit 20 volunteers as participants in the experiment. Each of the participating institutions (Sapienza University of Rome, University of Barcelona, University of Bern, and Egas Moniz University) will submit an application to their respective local bioethics committee for approval to conduct the medical experiment.
Eligibility Criteria To be eligible for the study, participants must have undergone previous implant treatment that has resulted in active, advanced peri-implantitis.
During the initial visit, patients will undergo a medical interview to document their systemic diseases and dental treatment history, with particular emphasis on:
The type and brand of implant The prosthetic loading type of the implant The location and time of implantation The onset and treatment history of peri-implantitis
Each participant will then undergo a dental examination, utilizing a UNC15 periodontal probe (DepplerSA, Roller, Switzerland). This assessment will include:
Oral hygiene indicators: Oral Hygiene Index (OHI), Aproximal Plaque Index (API) Periodontal disease indices: Community Index of Periodontal Treatment Needs (CPITN) Occlusal abnormalities and increased facial muscle tension, particularly in the mentalis muscle and oral floor muscles Implant-Specific Assessments
For the implant site, the following parameters will be evaluated:
Pocket Depth (PD) - measured on four surfaces around the implant Bleeding on Probing (BoP) Index Width and height of the attached gingiva (HKT, WKT) Possible implant mobility, assessed using the Mobility Index (MOB) Following the clinical examination, each participant will be referred for a Cone Beam Computed Tomography (CBCT) scan.
CBCT Examination
The CBCT scan will be routinely evaluated, focusing on the implant region, with measurements including:
Bone loss percentage, calculated as the ratio of bone defect depth from the implant platform to the base of the defect, relative to the total implant length, assessed separately for each of the four implant surfaces (mesial, distal, buccal, and lingual/palatal).
Bone density, measured in Hounsfield units (HU)
A peri-implantitis process will be classified as active if:
PD at the implant site exceeds 6mm, with a positive BoP index Advanced peri-implantitis is diagnosed if bone loss exceeds 66% on at least one implant surface Treatment Eligibility Criteria According to established literature, in cases of active, advanced peri-implantitis, where bone loss exceeds 50% of the implant length, implant removal is considered the appropriate therapeutic approach. Only patients meeting this criterion will be enrolled in the project.
Exclusion Criteria:
General and local contraindications for surgical procedures Pregnancy Use of bisphosphonates or other antiresorptive medications in medical history Patients who do not meet the implant removal criteria and are not eligible for the study will be directed toward non-surgical or conservative-surgical treatment options.
Laboratory Analysis Procedures
During a subsequent procedural visit, a 20ml venous blood sample will be collected from the antecubital vein of each participant. The blood samples will be preserved in EDTA tubes and sent to a laboratory for further analysis, including:
Hematological Inflammation Indices: Systemic Immune-Inflammation Index (SII), Aggregate Index of Systemic Inflammation (AISI), Complete blood count with quantitative and percentage analysis, Indicator of Peri-Implantitis and Periodontal Disease Development: morphology by quantitative and percentage separation, Lipid profile: (CHOL , HDL, LDL, TG, APOA1, APOB);
- Inflammatory markers: CRP, ESR, ALB, TP, TF, FIB;
- Cytokine profile: TNF, IL- 1β, IL-6, IL-8, IL-10;
- HOMA2 Parameters: Glucose, Insulin, C-Peptide, HBA1;
- Thyroid profile:- TSH, FT3, FT4, T3, T4, rT3;
- Vitamin D level - 25(OH)D, 1.25(OH)2 D3 Laboratory and Surgical Procedures Each partner institution will conduct laboratory tests and clinical procedures at their respective clinical locations, in collaboration with a certified analytical laboratory.
Next, each participant will undergo implant explantation surgery, during which tissue samples will be collected for further analysis, followed by immediate bone defect regeneration at the implantation site. The procedure will be preceded by removal of the prosthetic restoration.
Following oral disinfection with a 0.2% alcohol-based chlorhexidine solution, local infiltration anesthesia will be administered using 2% articaine with epinephrine 1:200,000. A flap incision will be performed to access the peri-implant region.
A trephine drill with the smallest possible diameter will then be selected to encompass the implant collar. Using the following drilling parameters-800 rpm, 20 Ncm torque, and 0.9% NaCl irrigation-the drill will be lowered to the apical depth of the implant. The implant will be extracted along with any bone tissue tightly adhered to its surface.
The implant and bone tissue will be preserved in a 5% formalin solution. The surgical site will be sutured using non-resorbable 5-0 monofilament sutures.
Both specimens will be sent to research centers in Poland. The implant and tissue samples will be transferred to the Department of Inorganic Chemistry, Analytical Chemistry, and Electrochemistry at the Silesian University of Technology in Gliwice, Poland.
Laboratory Analysis
In the laboratory, biological material will be separated from the samples. The following analyses will be performed:
Titanium concentration measurement and detection of other metals present in the titanium alloy.
Implant surface will be analysed using: Light microscopy, Scanning electron microscopy (SEM), corrosion testing. The microscopic examination will assess the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Post-Explantation Follow-Up
One week after the explantation procedure, a follow-up visit will take place. During this visit:
Surgical sutures will be removed. The healing process of the surgical wound will be assessed. If no complications are detected, the next follow-up visit will be scheduled four weeks later. During the four-week follow-up visit, the following evaluations will be performed:
Clinical assessment of the implantation site, including HKT and WKT parameters A second CBCT scan: to assess bone structure in the post-implantation region, with measurements including: Percentage of bone loss, calculated as the ratio of the smallest vertical dimension of the alveolar ridge in the post-implantation area to the height of the alveolar ridge in the immediate vicinity
Blood Sample Collection:
20ml of venous blood will be collected from the antecubital vein of each participant.
The blood sample will be preserved in EDTA tubes and sent to an analytical laboratory for further testing, including same parameters as mentioned previously.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Healthy adult participants, suffering from Peri-Implantitis. Every participant from a total number of 100 will have blood sample collected twice before and 4 weeks following implant removal for detailed evaluation. Furthermore, the Cone Beam Computed Tomography will be applied to evaluate the severity and shape of bone defect. Removed implants will be send for detailed chemical evaluation.
| Arm | Type | Receives |
|---|---|---|
| Study group | Experimental | Diagnostic Test: Blood testingEvery participant will achieve same intervention when it comes to surgical treatment, clinical examination, radiology evaluation and defined parameters of blood serum. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- PD (Pocket Depth) at the implant site exceeds 6mm,
- Positive BoP (Bleeding on Probing) index
- Bone loss exceeding 66% on at least one implant surface
Key exclusion criteria (3 listed)
- General and local contraindications for surgical procedures
- Pregnancy
- Use of bisphosphonates or other antiresorptive medications in medical history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood testingAlso: Radiation, SurgeryBlood sample will be collected twice for each participants procedding and following dental implant removal. Cone Beam Computed Tomography will be applied to evaluate the shape, severity of bone defect in direct viscinity of the implant. | Diagnostic test | Study group |
Primary outcome
Blood testing, total blood count, and indices derived from it.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Hematological Inflammation Indices: Systemic Immune-Inflammation Index (SII) calculated as follows: SII=NEUxPLT/LYMPH
Blood testing, total blood count, and indices derived from it.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Hematological Inflammation Indices: Aggregate Index of Systemic Inflammation (AISI) calculated as follows: AISI= NEU×PLTxMON/LYMP
Blood testing, lipid profile.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
CHOL mg/dl , HDL mg/dl, LDL mg/dl, TG mg/dl, APOA1 mg/dl, APOB mg/dl
Blood testing, Inflammatory markers.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Inflammatory markers: CRP mg/l, albumin (ALB) mg/dl, TP mg/dl,TF mg/dl, FIB mg/dl
Blood testing, Inflammatory marker.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
ESR mm/h
Blood testing, Cytokine profile.
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
TNF- α pg/ml , IL- 1β pg/ml, IL-6 pg/ml, IL-8 pg/ml, IL-10 pg/ml
Blood testing, HOMA2 Parameters
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
HOMA2 Parameters - Glucose mg/dl, C-Peptide mg/dl,
Blood testing, HOMA2 Parameters
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Insulin mU/ml
Blood testing, HOMA2 Parameters
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
HBA1C %
Blood testing, Thyroid profile
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
TSH μIU/ml
Blood testing, Thyroid profile
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
FT3 ng/l, FT4 ng/l
Blood testing, Thyroid profile
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
T3 ng/dl, T4 ng/dl
Blood testing, Thyroid profile
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
rT3 ng/ml
Blood testing, Vitamin D3 level
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
25(OH)D, 1.25(OH)2 D3 ng/ml
Clinical examination - general, oral cavity
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Oral Hygiene Index (OHI) %, Aproximal Plaque Index (API) %
Clinical examination - general, oral cavity, utilizing a UNC15 periodontal probe
Time frame: On the day of implant removal (before implant removal).
Community Index of Periodontal Treatment Needs (CPITN)
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Time frame: On the day of implant removal (before implant removal).
Pocket Depth (PD) - measured on four surfaces around the implant in mm.
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Time frame: On the day of implant removal (before implant removal).
Bleeding on Probing (BoP) Index - Yes or No. (0 or 1).
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Time frame: On the day of implant removal (before implant removal).
Width and height of the attached gingiva (HKT, WKT) in mm.
Clinical examination - implant site, utilizing a UNC15 periodontal probe
Time frame: On the day of implant removal (before implant removal).
Possible implant mobility, assessed using the Mobility Index (MOB) acc to Misch, Grade: 0,1,2 or 3
Radiology-based evaluation
Time frame: On the day of implant removal (before implant removal).
Cone-Beam Computed Tomography: Bone loss percentage on the implant site (%), calculated as the ratio of bone defect depth from the implant platform to the base of the defect, relative to the total implant length, assessed separately for each of the four implant surfaces (mesial, distal, buccal, and lingual/palatal)
Radiology-based evaluation
Time frame: On the day of implant removal (before implant removal) and 4 weeks after.
Cone-Beam Computed Tomography: Bone density on the implant site (before and after implant removal), measured in Hounsfield units (HU)
Implant surface evaluation, light microscopy
Time frame: Within 48 hours after implant removal
Assessment of the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Implant surface evaluation, Scanning electron microscopy
Time frame: Within 48 hours after implant removal
Assessment of the implant surface, identifying areas with fatigue-related material degradation, such as microcracks.
Implant surface evaluation - detection of other metals presented in the titanium alloy.
Time frame: Within 48 hours after implant removal
Energy-dispersive X-ray spectroscopy (EDS)
Titanium ions concentration in tissues attached to implant' surface
Time frame: Within 48 hours after implant removal
Inductively coupled plasma mass spectrometry (ICP-MS)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2025.
- Background: PubMed 30075090Elani HW, Starr JR, Da Silva JD, Gallucci GO. Trends in Dental Implant Use in the U.S., 1999-2016, and Projections to 2026. J Dent Res. 2018 Dec;97(13):1424-1430. doi: 10.1177/0022034518792567. Epub 2018 Aug 3.
- Background: PubMed 32844418Fu JH, Wang HL. Breaking the wave of peri-implantitis. Periodontol 2000. 2020 Oct;84(1):145-160. doi: 10.1111/prd.12335.
- Background: PubMed 27458093Schwarz F, Claus C, Becker K. Correlation between horizontal mucosal thickness and probing depths at healthy and diseased implant sites. Clin Oral Implants Res. 2017 Sep;28(9):1158-1163. doi: 10.1111/clr.12932. Epub 2016 Jul 26.
- Background: PubMed 29926957Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. J Periodontol. 2018 Jun;89 Suppl 1:S267-S290. doi: 10.1002/JPER.16-0350.
- Background: PubMed 27238274Albrektsson T, Canullo L, Cochran D, De Bruyn H. "Peri-Implantitis": A Complication of a Foreign Body or a Man-Made "Disease". Facts and Fiction. Clin Implant Dent Relat Res. 2016 Aug;18(4):840-9. doi: 10.1111/cid.12427. Epub 2016 May 30.
- Background: PubMed 26987886Pettersson M, Kelk P, Belibasakis GN, Bylund D, Molin Thoren M, Johansson A. Titanium ions form particles that activate and execute interleukin-1beta release from lipopolysaccharide-primed macrophages. J Periodontal Res. 2017 Feb;52(1):21-32. doi: 10.1111/jre.12364. Epub 2016 Mar 14.
- Background: PubMed 27190573Tsave O, Petanidis S, Kioseoglou E, Yavropoulou MP, Yovos JG, Anestakis D, Tsepa A, Salifoglou A. Role of Vanadium in Cellular and Molecular Immunology: Association with Immune-Related Inflammation and Pharmacotoxicology Mechanisms. Oxid Med Cell Longev. 2016;2016:4013639. doi: 10.1155/2016/4013639. Epub 2016 Apr 11.
- Background: PubMed 32305626Scibior A, Pietrzyk L, Plewa Z, Skiba A. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. J Trace Elem Med Biol. 2020 Sep;61:126508. doi: 10.1016/j.jtemb.2020.126508. Epub 2020 Apr 12.
- Background: PubMed 26996620Grande F, Tucci P. Titanium Dioxide Nanoparticles: a Risk for Human Health? Mini Rev Med Chem. 2016;16(9):762-9. doi: 10.2174/1389557516666160321114341.
- Background: PubMed 24931876Zhang HM, Cao J, Tang BP, Wang YQ. Effect of TiO(2) nanoparticles on the structure and activity of catalase. Chem Biol Interact. 2014 Aug 5;219:168-74. doi: 10.1016/j.cbi.2014.06.005. Epub 2014 Jun 12.
- Background: PubMed 32402439Chen WQ, Zhang SM, Qiu J. Surface analysis and corrosion behavior of pure titanium under fluoride exposure. J Prosthet Dent. 2020 Aug;124(2):239.e1-239.e8. doi: 10.1016/j.prosdent.2020.02.022. Epub 2020 May 10.
- Background: PubMed 9855202Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Effect of modification of oxide layer on NiTi stent corrosion resistance. J Biomed Mater Res. 1998 Winter;43(4):433-40. doi: 10.1002/(sici)1097-4636(199824)43:43.0.co;2-#.
- Individual participant dataSharing planned: Yes. All collected anonymized IPD will be available on Zenodo Repository.
Related trials for Peri-Implantitis
Not yet recruiting
Effect of Customized Versus Stock Healing Abutments on Peri-Implant Soft Tissue
Peri-Implantitis
RecruitingObservational study
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
Peri Implantitis, Peri Implant Mucositis
Not yet recruitingObservational study
Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs
Peri-implantitis, Alveolar Bone Loss
RecruitingObservational study
Access to Probing and Peri-implant Diseases
Peri-implantitis, Peri-implant Bone Loss
Not yet recruitingObservational study
ATR-FTIR and Raman Spectroscopy of Peri-Implant Crevicular Fluid in Peri-Implantitis
Peri-Implantitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marzena Dominiak, Prof study chair
Wroclaw Medical Univeristy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood testing in people with Peri-Implantitis, run by Wroclaw Medical University at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pawel Kubasiewicz-Ross, PhD, DDS (504075920 ext. +48, pawel.kubasiewicz-ross@umw.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood testing, total blood count, and indices derived from it. (time frame: On the day of implant removal (before implant removal) and 4 weeks after.). The study lists 26 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07012915, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2025.